Redefining the Future of Sickle Cell Care

Cook Children's hematologist, Clarissa Johnson MD with sickle cell patient Triston during RUBY treatment

As the only pediatric institution in Texas offering the RUBY Trial, Cook Children's is leading the way in innovative treatments for sickle cell disease (SCD). According to Gretchen Eames, M.D., Medical Director of the Stem Cell Transplant Program at Cook Children's, we were chosen for this trial because of our proven track record in research and patient outcomes. This trial uses experimental technology called EDIT-301 to modify a patient's own blood stem cells, an alternative to traditional stem cell transplants. Unlike these previous treatments requiring a matched donor, the RUBY Trial eliminates that need, using the patient's own cells to create healthier blood. While it's not a cure, it offers life-changing potential for those who qualify, helping to reduce painful flare-ups and frequent hospital visits.

Ashlynn Malone, who has lived with SCD her entire life, started participating in the Ruby Trial in 2023, hoping for lasting relief. While her journey is still ongoing, the results from patients like Triston Tate offer new hope. Triston became the first patient at Cook Children's to participate in the Ruby Trial. Before the procedure, he was hospitalized up to 100 times a year due to SCD. Seven months after the treatment, Taylor has not experienced a pain crisis and feels more energetic, even holding down a job and keeping up with his friends. Cook Children's commitment to innovative therapies, like the Ruby Trial, ensures that patients like Ashlynn and Triston have access to cutting-edge treatments, reinforcing our role at the forefront of medical care for SCD.

Redefining the Future of Sickle Cell Care

Explore more